null

Recombinant Cynomolgus Interleukin-17A/IL-17A (C-6His) (RPES6781)

SKU:
RPES6781
Product Type:
Recombinant Protein
Species:
Monkey
€159
Frequently bought together:

Description

Product Name:Recombinant Cynomolgus Interleukin-17A/IL-17A (C-6His)
Product Code:RPES6781
Size:10µg
Species:Cynomolgus macaques
Expression Host:HEK293 Cells
Synonyms:Interleukin-17A, IL-17, IL-17A, Cytotoxic T-Lymphocyte-Associated Antigen 8, CTLA-8, IL17A, CTLA8, IL17
Mol Mass:15.9 kDa
AP Mol Mass:15-25 kDa
Tag:C-6His
Purity:> 95 % as determined by reducing SDS-PAGE.
Endotoxin Level:< 1.0 EU per μg of the protein as determined by the LAL method.
Bio Activity:Immobilized Cynomolgus IL-17A-His at 10 μg/ml (100 μl/well) can bind Anti-Human IL-17A mAb. The ED50 of Anti-Human IL-17A mAb is 128 ng/ml.
Sequence:Gly24­Ala155
Accession:G7P4U9
Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping:This product is provided as lyophilized powder which is shipped with ice packs.
Formulation:Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution:Please refer to the printed manual for detailed information.
Background:Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Related Products